Core Laboratories (NYSE:CLB) Issues Earnings Results, Hits Estimates

Core Laboratories (NYSE:CLB) released its quarterly earnings results on Wednesday. The oil and gas company reported $0.06 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.06, FiscalAI reports. The firm had revenue of $121.80 million for the quarter, compared to the consensus estimate of $125.35 million. Core Laboratories had a return on equity of 12.18% and a net margin of 6.04%.The firm’s quarterly revenue was down 1.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.14 EPS. Core Laboratories updated its Q2 2026 guidance to 0.060-0.120 EPS.

Core Laboratories Price Performance

Shares of CLB traded down $2.87 during mid-day trading on Thursday, hitting $14.43. The company’s stock had a trading volume of 305,265 shares, compared to its average volume of 381,999. The company has a current ratio of 2.02, a quick ratio of 1.51 and a debt-to-equity ratio of 0.41. The firm has a 50-day simple moving average of $16.74 and a 200 day simple moving average of $16.69. The firm has a market capitalization of $664.36 million, a P/E ratio of 21.29, a P/E/G ratio of 3.25 and a beta of 1.15. Core Laboratories has a 1-year low of $9.72 and a 1-year high of $20.36.

Core Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 1st. Stockholders of record on Monday, May 11th will be issued a $0.01 dividend. This represents a $0.04 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, May 11th. Core Laboratories’s dividend payout ratio (DPR) is currently 5.97%.

Institutional Trading of Core Laboratories

Hedge funds have recently modified their holdings of the business. The Manufacturers Life Insurance Company lifted its holdings in shares of Core Laboratories by 6.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 17,932 shares of the oil and gas company’s stock valued at $207,000 after buying an additional 1,040 shares during the period. iSAM Funds UK Ltd acquired a new stake in shares of Core Laboratories in the 3rd quarter valued at approximately $202,000. Quantbot Technologies LP lifted its holdings in shares of Core Laboratories by 343.7% in the 2nd quarter. Quantbot Technologies LP now owns 17,520 shares of the oil and gas company’s stock valued at $202,000 after buying an additional 13,571 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Core Laboratories by 49.6% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,132 shares of the oil and gas company’s stock valued at $199,000 after buying an additional 5,345 shares during the period. Finally, Quantessence Capital LLC acquired a new stake in shares of Core Laboratories in the 3rd quarter valued at approximately $192,000. 97.81% of the stock is owned by institutional investors and hedge funds.

Core Laboratories News Roundup

Here are the key news stories impacting Core Laboratories this week:

• Positive Sentiment: Board-authorized capital returns: management repurchased 51,781 shares for roughly $0.9 million in Q1, showing continued buyback activity that supports shareholder value. PR Newswire Release
• Positive Sentiment: Quarterly dividend declared: Core announced a $0.01 per-share quarterly dividend (ex-dividend May 11; payable June 1), providing a modest yield and signaling some shareholder-return discipline.
• Neutral Sentiment: Reported EPS in line with expectations: CLB posted $0.06 EPS for Q1, meeting consensus estimates — a stabilization versus steeper sequential declines implied by other metrics. Quarterly Report
• Neutral Sentiment: Coverage and comparisons: industry write-ups and value-comparison pieces (e.g., TipRanks, Zacks) are examining CLB vs peers, which may attract bargain-hunting interest but do not change near-term fundamentals. TipRanks Article Zacks Article
• Negative Sentiment: Weaker Q2 guidance: management set Q2 EPS guidance of $0.060–$0.120 vs. the consensus ~$0.150 and revenue guidance below street expectations ($123M–$131M vs. ~$127.8M), signaling softer near-term demand and driving the share decline.
• Negative Sentiment: Revenue and profitability pressures: Q1 revenue was $121.8M (below analyst estimates), operating income was only $1.9M and GAAP reported a $0.02 loss per share; adjusted EPS and ex-items fell substantially year-over-year and sequentially. PR Newswire Release
• Negative Sentiment: Weak cash flow and higher leverage: free cash flow dropped to $0.5M and net debt increased by $3.9M (leverage ~1.20), reducing financial flexibility and raising near-term execution risk.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “hold (c)” rating on shares of Core Laboratories in a research note on Friday, March 27th. Four equities research analysts have rated the stock with a Hold rating, According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $12.50.

About Core Laboratories

Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.

The company’s portfolio spans two primary service lines: reservoir description and production enhancement.